TY-JOURT1-剖析对肺动脉高压病人肺容和血液气体的影响JF-EurResir JOO-EurRespr JDO-10.183/139993003.01070-2023SP-23070AU-Olsson-KarenMAU-Fuge、JanAU-Park、Da-EU-KampAU-Brod,TorbenAU-Harrigfeld,BrittaAU-Schupp,JonasCoeper, MariusMY1-2023/01UR-//www.qdcxjkg.com/content/ears/2023/07/13/13993003.01070-2023.abstric N2-脉冲高压PAH大部分症状和信号归结为右心功能缺陷PAH病人的肺扩散能力可变改变一氧化碳和气体交换,导致疾病症状和严重性。Footots本手稿最近被欧洲呼吸杂志接受出版本文先以接受形式发布后由制作团队拷贝和排版完成制作过程后, 作者批准生成证明后, 文章将转至最新一期ERJ在线版Please open or download the PDF to view this article.Conflict of interest: KM Olsson has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, Ferrer, GSK, Janssen, MSD, Pfizer, and United Therapeutics.Conflict of interest: J Fuge has received personal fees/speaker honoraria from AstraZeneca outside the submitted work.Conflict of interest: DH Park is supported by PRACTIS – Clinician Scientist Program at Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3-1).Conflict of interest: JC Kamp is supported by PRACTIS – Clinician Scientist Program at Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3-1).Conflict of interest: T Brod has no disclosures.冲突:JC Schupp对肺纤维化新疗法拥有专利权并接受BehringerIngelheim教程费 冲突:MMHHeper报告教程费和/或咨询费来自Acceron、Actelion、Altavant、AOPHealth、Bayer、Ferrer、Janssen和MSD,并有MSD提交专利应用申请#63466014,提高肺动脉高压病人传播能力方法ER-